17 results about "Cerebral Thrombus" patented technology

This paper presents a medical device for treating traumatic brain injury and cerebral thrombosis through electroacupuncture. The device includes a 6-DOF (degree of freedom) mechanical arm, a multifunctional tool tip, an MRI helmet suitable for acupuncture, and magnetic resonance imaging (MRI). The acupuncture robot can insert needles and automatically manipulate specific needles by rotating or vibrating them within a specific frequency range, and can enhance the effect by applying electrical stimulation.

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

This application relates to the technical field of exosome preparation, specifically disclosing a pharmaceutical component for the prevention and treatment of sequelae of cerebral thrombosis, its preparation method, and its application. The pharmaceutical component comprises Exo-miR-17-92 and Exo-miR-30d-5p; it is obtained by secretion from mesenchymal stem cells capable of simultaneously overexpressing the genes miR-17-92 and miR-30d-5p; the sequence of the gene miR-17-92 is shown in SEQ ID NO:1, and the sequence of the gene miR-30d-5p is shown in SEQ ID NO:2. The pharmaceutical component of this application, comprising Exo-miR-17-92 and Exo-miR-30d-5p, exerts a significant and excellent therapeutic effect on sequelae of cerebral thrombosis through the synergistic effect of their expression products.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine pellet preparation for promoting blood circulation and dredging channels and a preparation method thereof. The pellet preparation is prepared from astragalus membranaceus, salvia miltiorrhiza, American ginseng, angelica sinensis, safflower carthamus, peach kernels, radix paeoniae rubra, leeches, earthworms, sappan wood, ground beetles, dandelions, golden cypress, rhizoma dioscoreae nipponicae, mulberry twigs, radix achyranthis bidentatae, eucommia ulmoides and gastrodia elata as raw materials and starch, lactose and microcrystalline cellulose as auxiliary materials. The pellet preparation is exact in curative effect and less in toxic and side effects, has the effects of reinforcing qi and nourishing yin, extinguishing wind and eliminating evil, and promoting blood circulation to remove meridian obstruction, and is used for treating sequelae of cerebral thrombosis, cerebral infarction and cerebral hemorrhage.

The invention belongs to the technical field of medical auxiliary screening, and provides a method for establishing a cerebral thrombosis prediction model based on Logistic aiming at the problem that various indexes of clinical blood biochemical detection are not combined for early prediction of cerebral thrombosis at present. The cerebral thrombosis risk is evaluated by taking age, serum ions, serum enzymology, lipolylogy, protein, glycometabolism and other low-cost and easily-obtained biochemical indexes as independent variables, and a cerebral thrombosis prediction model is established in combination with Logistic regression analysis. The sensitivity of the cerebral thrombosis prediction model provided by the invention is 0.841, and the specificity of the cerebral thrombosis prediction model is 0.876. And the accuracy of prediction by using clinical data reaches 83.7%, and the method has good operability and is worthy of clinical application and popularization.

The invention provides syringic acid as well as preparation, a pharmaceutical composition and medical application thereof. The purity of the syringic acid is 95% or above, and the syringic acid can be extracted from motherwort. The syringic acid disclosed by the invention has a good dissolving effect on fibrin in thrombus formation, is relatively high in blood-brain barrier transmittance, has thrombus dissolving and antithrombotic effects, and can be used for preparing medicines for treating thrombotic diseases. The syringic acid can be processed into oral preparations such as tablets, capsules, granules, dripping pills and other common preparations or sustained release preparations, injection preparations such as injection freeze-dried powder injections, and external preparations such as ointments or emulsifiable paste according to a conventional production process of pharmaceutics, and is used for treating thrombotic diseases, especially cerebral thrombosis diseases.

The invention discloses a traditional Chinese medicine composition for treating cerebral thrombosis precursor and later rehabilitation. The traditional Chinese medicine composition is prepared from radix salviae miltiorrhizae, rhizoma atractylodis macrocephalae fried with soil, pericarpium citri reticulatae, fried malt, fructus crataegi, fried fructus aurantii immaturus, mulberries and semen cassiae. The medicine is prepared from the following raw materials in parts by weight: 7-15 parts of radix salviae miltiorrhizae, 6-15 parts of rhizoma atractylodis macrocephalae fried with soil, 6-12 parts of pericarpium citri reticulatae, 5-10 parts of fried malt, 12-20 parts of fructus crataegi, 18-25 parts of fried fructus aurantii immaturus, 5-16 parts of mulberries and 10-30 parts of semen cassiae. The traditional Chinese medicine composition can effectively improve cerebral thrombosis precursor symptoms and promote later rehabilitation, is safe and free of side effects, can be prepared into various dosage forms for clinical treatment, and has a good application prospect.

The present application belongs to the technical field of bioengineering, and particularly relates to a tuna fish bone antioxidant oligopeptide and a preparation method thereof.The tuna fish bone antioxidant oligopeptide has good scavenging activity, and has good thermal stability and digestion resistance; the mechanism of action is to promote the release of nitric oxide (NO), improve the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), catalase (CAT) and total antioxidant capacity (T-AOC), and reduce the levels of malondialdehyde (MDA) and lactate dehydrogenase (LDH); JQYG-1 can protect HUVEC cells from oxidative damage induced by hydrogen peroxide; JQYG-1 can exert an antioxidant effect and protect vascular endothelial cells, and can provide a candidate drug for the prevention and treatment of cardiovascular and cerebrovascular diseases such as hypertension, coronary heart disease, cerebral thrombosis, myocardial infarction, atherosclerosis and heart failure.

This invention discloses two traditional Chinese medicine compositions, namely, Composition I and Composition II, for use in the recovery period of cerebral thrombosis, and their medicinal uses. Composition I comprises 400-700 parts by weight of Astragalus membranaceus, 200-400 parts by weight of Panax notoginseng, 100-350 parts by weight of Hirudo medicinalis, and 1-10 parts by weight of Borneol. Composition II comprises 50-120 parts by weight of Astragalus membranaceus extract, 20-40 parts by weight of total Panax notoginseng saponins, 20-50 parts by weight of Hirudo medicinalis extract, and 1-10 parts by weight of Borneol. This invention also provides a drug comprising Composition I or Composition II, its preparation method, and its medicinal uses.

The invention relates to the technical field of body conditioning medicines, in particular to a medicine formula for conditioning a circulation system in a body and a preparation process of the medicine formula. The invention relates to a medicine formula for conditioning in-vivo circulation system and a preparation process thereof, the medicine formula comprises a main material and an auxiliary material, and is characterized in that the main material is prepared by mixing the following raw materials by weight: 16-22g of salvia miltiorrhiza, 8-12g of astragalus membranaceus, 1-5g of pseudo-ginseng powder, 18-22g of fried spina date seed, 6-15g of ginseng, 6-12g of borneol, 18-24g of folium artemisiae argyi and 8-14g of borneol; the auxiliary material is prepared by mixing the following raw materials by weight: 10-20 g of poria cocos, 8-15 g of bighead atractylodes rhizome, 10-15 g of cassia twig, 20-25 g of dried ginger, 13-26 g of cornu cervi pantotrichum, 5-12 g of herba epimedii, 11-22 g of rhizoma polygonati, 18-28 g of codonopsis pilosula, 17-25 g of angelica sinensis and 15-30 g of chrysanthemum. The formula has the beneficial effects that the formula is scientific in preparation, balanced in nutrition and proper in proportion, has the effects of balancing yin and yang, coordinating internal organs, removing blood stasis and dissipating binds and the like, and can prevent and condition cardiovascular and cerebrovascular diseases, cerebral thrombosis, hypertension, coronary heart disease, heart failure, arrhythmia, rheumatic heart disease, palpitation, chest pain, headache, hemiplegia of half limbs, cerebral infarction and other diseases.

The present application relates to the field of biomedicine technology, and more particularly to a plant extract composition and its application. The plant extract composition comprises a water-soluble tomato concentrate and an Ampelopsis grossularis extract. Compared to conventional technologies, the beneficial effects of the embodiments of the present application include: the plant extract composition comprising a water-soluble tomato concentrate and an Ampelopsis grossularis extract provided in the embodiments of the present application has a synergistic effect in improving blood flow and / or inhibiting platelet aggregation, and preventing and treating cerebral thrombosis. The combined use of the water-soluble tomato concentrate and Ampelopsis grossularis extract significantly improves the effect compared to the use of a single extract, greatly reduces the cost, and has excellent application prospects.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and discloses a TCM composition, preparation method, and oral formulation for treating cardiovascular and cerebrovascular diseases of the Qi deficiency and blood stasis type. The TCM composition is made from kudzu root, astragalus root, notoginseng, safflower, chuanxiong rhizome, hawthorn, angelica root, polygonum cuspidatum, licorice root, and salvia miltiorrhiza in specific weight parts. A preferred ratio is 60 parts kudzu root, 60 parts astragalus root, 25 parts notoginseng, 30 parts safflower, 25 parts chuanxiong rhizome, 30 parts hawthorn, 25 parts angelica root, 25 parts polygonum cuspidatum, 10 parts licorice root, and 26 parts salvia miltiorrhiza. It can be used for coronary heart disease, cerebral arteriosclerosis, cerebral thrombosis, hyperlipidemia, or sequelae of cerebral infarction. In preparation, the medicinal materials are cleaned, dried, mixed, and pulverized into a fine powder, passed through a 120-180 mesh sieve, and then formed into water pills using water as a binder. After drying and packaging, the product is obtained. This invention has a scientific formulation and precise proportions, making it suitable for the long-term prevention and treatment of cardiovascular and cerebrovascular diseases of the Qi deficiency and blood stasis type.

The invention relates to a medicine for treating cerebral thrombosis, cerebral thrombosis precursor and cerebral thrombosis sequelae. Comprising the following raw materials in parts by weight: 15-30 parts of astragalus membranaceus, 10-20 parts of ligusticum wallichii, 10-20 parts of radix paeoniae rubra, 10-20 parts of gastrodia elata, 2-5 parts of scorpion, 10-20 parts of pseudo-ginseng, 10-20 parts of rhizoma corydalis, 10-20 parts of radix clematidis, 10-20 parts of earthworm, 10-20 parts of honeysuckle stem, 10-20 parts of ginkgo leaf, 1-3 parts of centipede, 10-20 parts of cassia twig, 2-5 parts of leech and 10-20 parts of herba siegesbeckiae. The traditional Chinese medicine is orally taken and externally applied, and has the effects of dispersing blood stasis, relieving spasm, activating blood, relieving pain, tonifying qi and nourishing blood.

This invention discloses a cerebral thrombosis removal device, comprising an outer cannula, a first catheter, a thrombus fragmentation structure, and an artificial blood vessel. The proximal and distal ends of the outer cannula respectively form a first inlet and a first outlet communicating with a first channel. The first catheter is disposed within the first channel. The thrombus fragmentation structure includes a second catheter and a fragmentation section located distal to the second catheter. The second catheter is movably disposed within the first catheter and can extend from the first outlet to fragment the thrombus at the target lesion site. An aspiration channel is formed inside the second catheter, with its distal opening located near the fragmentation section for aspirating the fragmented thrombus fragments. The artificial blood vessel includes a third catheter, the distal end of which is used to cross the thrombus at the target lesion site to reach a distal blood vessel and deliver blood to temporarily relieve ischemia. This invention's cerebral thrombosis removal device can extend the safe surgical time window.

The invention belongs to the technical field of medicines, and particularly relates to application of novel glycyrrhizol in preparation of products for preventing or treating ischemic encephalopathy, and the ischemic encephalopathy comprises cerebral thrombosis, cerebrovascular stenosis / occlusion and cerebral atherosclerosis. According to the application disclosed by the invention, the novel glycyrrhizol is used for treating the ischemic encephalopathy for the first time, and experiments show that the novel glycyrrhizol has a remarkable treatment effect on the ischemic encephalopathy, can be used for obviously improving behavioral scores, cerebral thrombosis and vascular diameter conditions after ischemia and reducing the volume of cerebral infarction, and has a good treatment effect on cerebral thrombosis and middle artery embolism. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

The invention belongs to the technical field of neural stem cell culture, and particularly relates to neural stem cells for treating cerebrovascular and cerebral thrombosis diseases and a culture method. The neural stem cell culture medium for treating cerebrovascular and cerebral thrombosis diseases comprises: (1) a basic culture medium; (2) cecropin, wherein the concentration of the cecropin in the basic culture medium is 5-10 [mu] g / mL; (3) a plant extract, wherein the concentration of the plant extract in the basic culture medium is 10-20 [mu] g / mL; and (4) bletilla striata exosome, wherein the concentration of the bletilla striata exosome in the basal culture medium is 10-20 [mu] g / mL. According to the culture medium, under the condition that the basic culture medium is added, the cecropin, the plant extract and the bletilla striata exosome are additionally added, through the synergistic effect of the cecropin, the plant extract and the bletilla striata exosome, the value-added stability in the neural stem cell culture process is facilitated, meanwhile, the neural stem cells can keep the cell characteristics of the neural stem cells, and the culture efficiency is improved. The preparation efficiency of the neural stem cells is improved.

The invention provides a motherwort phenolic acid extract with a thrombolysis effect as well as a preparation method and application of the motherwort phenolic acid extract. The method provided by the invention can effectively extract the effective part with fibrinolysis effect in motherwort; the herba leonuri phenolic acid extract is mainly prepared from vanillic acid, syringic acid, trans-ferulic acid, cis-ferulic acid and 3, 4, 5-trimethyl gallic acid, and the total content of the herba leonuri phenolic acid extract is not lower than 70%. The herba leonuri phenolic acid extract has a good dissolving effect on fibrin in thrombosis, has thrombus dissolving and antithrombotic effects, and can be processed into various common preparations or sustained release preparations such as oral preparations such as tablets, capsules, granules and dropping pills according to a conventional production process of pharmaceutics; injection preparations such as injection freeze-dried powder injections and external preparations such as ointment and emulsifiable paste are used for treating thrombotic diseases (including cerebral thrombosis and subcutaneous blood stasis).